| Company (Symbol) | Product | Description | Indication | Action (Date) |
| Maxim Pharmaceuticals Inc. (MAXM) | Maxamine | Histamine dihydrochloride; H2 receptor agonist | Stage IV malignant melanoma | Submitted NDA (7/10); FDA designated Maxamine for priority review; NDA was submitted in July (9/7); FDA s Oncologic Drugs Advisory Committee recommended against the NDA for Maxamine as an adjuvant to interleukin-2 to treat patients who have liver metastases (12/13) |
